When Conventional Heart Failure Therapy is not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor or Aldosterone Antagonist?
|
|
- Austin Garrison
- 5 years ago
- Views:
Transcription
1 When Conventional Heart Failure Therapy is not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor or Aldosterone Antagonist? Sripal Bangalore, MD, MHA, Sunil Kumar, MD, Franz H Messerli, MD, New York University School of Medicine, New York, NY [SB] University of Nebraska, Omaha, NE [SK] St. Luke s-roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, NY [FHM]
2 Disclosure Information Sripal Bangalore: Advisory board- Daiichi Sankyo Sunil Kumar: None Franz H. Messerli: Consulting: Abbott, Novartis, Pfizer, Bayer, Forest, Daiichi-Sankyo, Sanofi, Medtronics and research/grants from Servier, Forest, and Novartis.
3 I IIa IIb III The addition of an ARB may be considered in persistently symptomatic patients with reduced LVEF who are already being treated with conventional therapy I IIa IIb III Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who can be carefully monitored for preserved renal function and normal potassium concentration Jessup et al. Circulation. 2009;119:
4 I IIa IIb III An ARB is recommended in patients with HF and an LVEF 40% who remain symptomatic despite optimal treatment with an ACEI and b-blocker, unless also taking an aldosterone antagonist I IIa IIb III Addition of a low-dose of an aldosterone antagonist should be considered in all patients with an LVEF 35% and severe symptomatic HF. Aldosterone antagonists reduce hospital admission for worsening HF and increase survival when added to existing therapy, including an ACEI Dickstein et al. European Heart Journal (2008) 29,
5 However, both sets of guideline warn against the combination of dual RAS blockade ( ACEi + ARB) with an aldosterone antagonist
6 Objectives To evaluate the appropriate treatment option in patients with heart failure who remain symptomatic on conventional heart failure therapy (BB, ACEi and Diuretic)
7 Methods: Search & Eligibility Criteria PUBMED, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) searches for randomized clinical trials (RCTs) Eligible trials had to fulfill the following criteria: RCTs comparing the above drug classes Cohort enrolled being heart failure with reduced systolic function on conventional heart failure therapy (including diuretics, beta blockers and angiotensin converting enzyme inhibitors) Follow-up of at least 3 months Enrolling at least 100 patients Able to report the outcomes of interest
8 Study Outcomes Efficacy outcomes Death Cardiovascular (CV) death Heart failure hospitalization Composite of CV death or heart failure hospitalization Safety outcomes Hyperkalemia Renal failure Hypotension
9 Statistical Analyses Mixed treatment comparison methods were used to compare the different treatment regimens using WinBUGS code Trials were grouped into 4 categories: placebo; ARBs, aldosterone antagonists and DRIs A random-effects Poisson regression model was fitted, taking into account the correlation structure induced by the multi-arm trials The analysis used the rate of efficacy and safety outcomes per 1000 person-years to obtain the log rate ratios of one treatment relative to another treatment Calculation of the probability that each treatment is best (lowest event proportion) was performed using a Bayesian Markov chain Monte Carlo method Minimally informative prior distributions were used for comparisons of treatments, so the findings are close to those obtained with frequentist methods
10 Results: Study Selection Records identified using terms Heart failure, RCT and Human = 5702 Trials excluded for not involving an ARB, DRI or AA=5502 Full-text articles assessed for eligibility (n = 200) Full-text articles excluded due to total number of patients less than 100 or total duration of study less than 3 months (n = 169) Studies included in qualitative synthesis (n = 31) Trials excluded (N=15) Outcome of interest not reported (n=6) Case control studies (n=3) Duplicate publication (n=3) Meta-analysis (n=3) Trial included in the meta-analysis = 16
11 Network of Treatment Comparisons Placebo ARBs AAs DRIs
12 Results: All cause Mortality Placebo (Ref) ARBs vs. Placebo AA vs. Placebo DRI vs. Placebo Rate Ratio (95% CrI) 0.96 (0.80, 1.17) 0.79 (0.66, 0.98) 1.75 (0.67, 4.50) ARBs (Ref) AA vs. ARBs 0.83 (0.63, 1.09) DRI vs. ARBs 1.84 (0.67, 4.67) AA (Ref) DRI vs. AA 2.20 (0.85, 5.81)
13 Results: CV Death Placebo (Ref) ARBs vs. Placebo AA vs. Placebo DRI vs. Placebo Rate Ratio (95% CrI) 0.94 (0.78, 1.07) 0.78 (0.65, 0.93) 1.95 (0.71, 5.69) ARBs (Ref) AA vs. ARBs 0.84 (0.66, 1.08) DRI vs. ARBs 2.10 (0.76, 6.16) AA (Ref) DRI vs. AA 2.48 (0.91, 7.31)
14 Results: HF Hospitalization Placebo (Ref) ARBs vs. Placebo AA vs. Placebo Rate Ratio (95% Cr I) 0.84 (0.68, 1.04) 0.74 (0.55, 0.94) DRI vs. Placebo 1.57 (0.21, 11.33) ARBs (Ref) AA vs. ARBs 0.88 (0.61, 1.21) DRI vs. ARBs 1.86 (0.26, 13.92) AA (Ref) DRI vs. AA 2.14 (0.29, 15.67)
15 Results: CV Death or HF Hospitalization Placebo (Ref) ARBs vs. Placebo AA vs. Placebo Rate Ratio (95% Cr I) 0.93 (0.77, 1.18) 0.73 (0.55, 0.90) DRI vs. Placebo 1.09 (0.57, 2.03) ARBs (Ref) AA vs. ARBs DRI vs. ARBs 0.78 (0.53, 1.04) 1.17 (0.58, 2.26) AA (Ref) DRI vs. AA 1.50 (0.78, 2.99)
16 Results: Hyperkalemia Placebo (Ref) Rate Ratio (95% Cr I) ARBs vs. Placebo 2.38 (1.20, 5.26) AA vs. Placebo 2.10 (1.29, 4.14) DRI vs. Placebo 2.48 (0.86, 7.49) ARBs (Ref) AA vs. ARBs DRI vs. ARBs 0.89 (0.37, 2.35) 1.04 (0.27, 3.76) AA (Ref) DRI vs. AA 1.18 (0.32, 3.81)
17 Results: Renal Failure Placebo (Ref) Rate Ratio (95% Cr I) ARBs vs. Placebo 2.26 (1.14, 6.51) AA vs. Placebo 1.38 (0.67, 3.87) DRI vs. Placebo 2.52 (0.62, 11.72) ARBs (Ref) AA vs. ARBs 0.61 (0.18, 2.11) DRI vs. ARBs 1.08 (0.18, 6.01) AA (Ref) DRI vs. AA 1.79 (0.31, 9.53)
18 Results: Hypotension Placebo (Ref) ARBs vs. Placebo Rate Ratio (95% Cr I) 1.63 (1.30, 2.62) AA vs. Placebo 1.35 (0.78, 2.41) DRI vs. Placebo 1.98 (1.02, 4.07) ARBs (Ref) AA vs. ARBs 0.83 (0.39, 1.43) DRI vs. ARBs 1.20 (0.51, 2.51) AA (Ref) DRI vs. AA 1.48 (0.62, 3.60)
19 Efficacy Outcomes and Probability Best* Treatment Death Rate Rate (95% Cr I) Probability Best CVDeath Rate (95% Cr I) Probability Best HF Hospitalization Rate (95% Cr I) Probability Best CV death or HF Hospitalization Rate (95% Cr I) Probability Best Placebo (25.61, 66.33) 0.7% (19.62, 57.77) 0.2% (77.49, 113.3) 0.2% (141.7, 178.6) 0.1% ARBs (23.74, 65.24) 4.9% (17.95, 55.20) 6.2% (60.56, 102.9) 12.9% (119.2, 190.1) 3.1% AA (19.49, 54.58) 89.1% (15.06, 46.07) 89.9% (50.13, 92.21) 68.8% (85.8, 145.3) 86.9% DRIs (25.59, 191.6) 5.3% (20.91, 215.1) 3.7% (21.77, 965.5) 18.2% (94.5, 316.0) 9.9% *Bayesian Markov chain Monte Carlo method
20 Safety Outcomes and Probability Best* Treatment Hyperkalemia Rate (95% CR I) Probability Best Renal Failure Rate (95% CR I) Probability Best Hypotension Rate (95% CR I) Probability Best Placebo (11.30, 22.10) 94.7% 11.8 (7.30, 17.24) 73.9% (21.12, 33.03) 84.3% ARBs (18.59, 82.73) 0.8% 27.4 (11.78, 69.07) 1.3% (33.39, 66.58) 0.1% AA (20.64, 61.85) 0.3% (7.68, 39.61) 16.8% (20.70, 61.21) 13.5% DRIs (13.08, ) 4.2% 29.9 (6.83, ) 8.0% (26.59, ) 2.1% *Bayesian Markov chain Monte Carlo method
21 Limitations As in other meta-analyses, given the lack of data in each trial, we did not adjust our analyses for dosage of medications used or with compliance to assigned treatment The percentage of patients on beta-blockers and those who received ICD/CRT was low in a few trials that reported this data Only limited number of trials involving DRI s and it is possible that the results might change when newer trials which larger sample size show any beneficial effect of DRI s
22 Conclusions (1) When compared with placebo, addition of aldosterone antagonist rather than ARBs or DRIs resulted in a significant reduction of death, cardiovascular death, heart failure hospitalization or the composite of cardiovascular death or heart failure hospitalization ARBs were associated with significant increase in the rate of hyperkalemia, renal failure or hypotension Aldosterone antagonists were associated with increase in hyperkalemia and DRI with increase in hypotension
23 Conclusions (2) In patients with heart failure and reduced systolic function who remain symptomatic on conventional heart failure medications including angiotensin converting enzyme inhibitors, the risk benefit ratio favors the addition of aldosterone antagonists over ARBs or DRIs
Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial
Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Sripal Bangalore, MD, MHA, Chuan-Chuan Wun, PhD, David A DeMicco, PharmD,
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationHeart failure. Complex clinical syndrome. Estimated prevalence of ~2.4% (NHANES)
Heart failure Complex clinical syndrome caused by any structural or functional impairment of ventricular filling or ejection of blood Estimated prevalence of ~2.4% (NHANES) Etiology Generally divided into
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationJoo-Yong Hahn, MD/PhD
Sungkyunkwan University School of Medicine Joo-Yong Hahn, MD/PhD Heart Vascular Stork Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Grant support Korean Society of Interventional
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationImplantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred
Implantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred Professor John GF Cleland University of Hull Kingston-upon-Hull United Kingdom Conflict of Interest: Funding or Speakers
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationRESEARCH. Sripal Bangalore, 1 Robert Fakheri, 1 Simon Wandel, 3 Bora Toklu, 2 Jasmin Wandel, 4 Franz H Messerli 5,6,7. open access
open access Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials Sripal Bangalore, 1 Robert
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationin patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationAldosterone synthase inhibitors. John McMurray BHF Cardiovascular Research Centre University of Glasgow
Aldosterone synthase inhibitors John McMurray BHF Cardiovascular Research Centre University of Glasgow Inhibition of aldosterone synthesis is hypothesized to be of benefit to patients with cardiovascular
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationWhat s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)
What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE Marc Ferrini (Lyon Fr) Palermo (I) 1 04 2017 Consulting Fees, Honoraria: BAYER PHARMA BOEHRINGER INGELHEIM BRISTOL MEYERS
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationNurse-sensitive factors in hypertension management
Nurse-sensitive factors in hypertension management Hypertension treatment State of the Art Copper Hall 14:45-15:04 02/04/2011 Philippe van de Borne, MD, PhD Department of cardiology ULB-Erasme Hospital
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationChronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)
Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update) NICE guideline Apendix C The algorithms Draft for consultation, January 2010 Chronic
More informationHeart Failure Medications: Who Needs What Drug Now? Disclosures
Heart Failure Medications: Who Needs What Drug Now? Simon Jackson MD FRCPC MMedEd Professor of Medicine (Cardiology) Dalhousie 1 Disclosures Honoraria and educational grants from: Actelion (medications
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationEffect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial
Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo P. Maggioni, MD, FESC Associazione Nazionale Medici
More information*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.
Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationeplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd
eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd 08 June 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationOLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,
The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,
More informationThe RealiseAF registry:
The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf
More information*NOTE: When reporting C P T code and 99239, it is recommended the measure be reported each time the code is submitted for hospital discharge.
Measure #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 2014 PQRS OPTIONS
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More informationBeta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center
Beta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center Beta-blockers: What s known 30 Years 30 Careers Physician clarity regarding
More informationACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)
ACP Brief Fall 2006 prioritization Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF) Background This topic was submitted by BC PharmaCare during
More informationPerioperative β blockers in patients having non-cardiac surgery: a meta-analysis
Perioperative β blockers in patients having non-cardiac surgery: a meta-analysis Sripal Bangalore, Jørn Wetterslev, Shruthi Pranesh, Sabrina Sawhney, Christian Gluud, Franz H Messerli Summary Background
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationSaudi Heart Failure Guidelines. Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group
Saudi Heart Failure Guidelines Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group Heart Failure Expert committee The Heart Failure Expert Committee,
More informationByvalson. (nebivolol, valsartan) New Product Slideshow
Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationMasked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationUse of Sacubitril/Valsartan in Heart Failure
Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationnephropathy and/or chronic kidney disease Summary of recommendations
July 2017 Guidelines: Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION SACUBITRIL/VALSARTAN (Entresto Novartis Pharmaceuticals) Indication: Heart Failure With Reduced Ejection Fraction Recommendation: The Canadian
More information